Haematologica
HAEMATOL/2017/165001
Version 3

Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Delphine Rea, Guylaine Henry, Zena Khaznadar, Gabriel Etienne, François Guilhot, Franck Nicolini, Joelle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci-Bresler, Aude Charbonnier, Frédéric Maloisel, Jean-Christophe Ianotto, Bruno Villemagne, François-Xavier Mahon, Hélène Moins-Teisserenc, Nicolas Dulphy, and Antoine Toubert

Disclosures: Funding This work was supported by research grants from the Association pour la Recherche sur le Cancer (Z.K., #DOC20100600956), Association LMC France (#R13102HH), Assistance Publique-Hôpitaux de Paris (Translational Research Grant in Biology 2010 #RTB10002) and French Ministry of Health/Institut National du Cancer (Programme Hospitalier de Recherche 2006). Disclosure of conflict of interest DR has received honoraria from Ariad, Bristol Myers Squibb, Novartis and Pfizer. GE has consulted for Bristol Myers Squibb and Novartis and is a member on an entity's board of directors or advisory committees for Ariad, Bristol Myers Squibb, Novartis, and Pfizer. FG has consulted for Celgene and Pfizer and has received honoraria from Celgene, Novartis and Pfizer. FH has received honoraria from Bristol Myers Squibb, Incyte, Novartis and Pfizer. LL has received research grants from Novartis and Pfizer and honoraria from Ariad. FM has received hospitality from Novartis and Roche and honoraria from Pfizer and Hospira. FN, JG, PR, MG, VD, AG-B, AC, BV, F-XM have not declared any conflict of interest. J-CI, GH, ZK, HM-T, ND and AT have no competing financial interests.

Contributions: Authorship contributions DR, ND and AT conceived the study, designed experiments and interpreted results; DR, GH, ZK and ND performed the experiments and undertook data analysis; DR and JG performed statistical analyses. F-XM was responsible for the STIM trial coordination and provision of clinical and outcome data. DR, ND and AT wrote the manuscript. All the other authors were investigator of the STIM trial and critically reviewed and approved the manuscript.